Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Hangzhou Tigermed Consulting Co EV-to-FCF?
Hangzhou Tigermed Consulting CoFRA:5HZ1 +5.05%88 EV-to-FCF is 44.77 as of Jul. 15, 2026, which is 46% below its 10-year median of 82.36. GuruFocus rates FRA:5HZ1 with a GF Score™ of 88/100 and a GF Value™ of €5.01 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 99 Medical Diagnostics & Research companies, Hangzhou Tigermed Consulting Co ranks worse than 71.72% on this metric.
The historical rank and industry rank for Hangzhou Tigermed Consulting Co's EV-to-FCF or its related term are showing as below:
FRA:5HZ1'
s EV-to-FCF Range Over the Past 10 Years
Min: 30.7 Med: 82.36 Max: 245.02
Current: 42.23
During the past 13 years, the highest EV-to-FCF of Hangzhou Tigermed Consulting Co was 245.02. The lowest was 30.70. And the median was 82.36.
FRA:5HZ1's EV-to-FCF is ranked worse than 71.72% of 99
companies
in the Medical Diagnostics & Research industry
Industry Median: 25.47
vs FRA:5HZ1: 42.23
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Hangzhou Tigermed Consulting Co (FRA:5HZ1) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Hangzhou Tigermed Consulting Co's PE Ratio (TTM) for today is calculated as:
Hangzhou Tigermed Consulting Co's share price for today is €4.16.
Hangzhou Tigermed Consulting Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.110.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Hangzhou Tigermed Consulting Co EV-to-FCF Related Terms
Hangzhou Tigermed Consulting Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Hangzhou Tigermed Consulting Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hangzhou Tigermed Consulting Co EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Hangzhou Tigermed Consulting Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Hangzhou Tigermed Consulting Co's EV-to-FCF falls into.
Hangzhou Tigermed Consulting Co's current Enterprise Value is €5,571.3 Mil.
Hangzhou Tigermed Consulting Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €124.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hangzhou Tigermed Consulting Co (FRA:5HZ1) has a EV-to-FCF of 44.77 as of Jul. 15, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Hangzhou Tigermed Consulting Co and its competitors. This is 46% below median its historical median of 82.36. Over the past decade, Hangzhou Tigermed Consulting Co's EV-to-FCF has ranged from 30.70 to 245.02. According to the industry distribution chart, Hangzhou Tigermed Consulting Co ranks #71 out of 99 companies in the Medical Diagnostics & Research industry, placing it in the top 71.7%.
Is Hangzhou Tigermed Consulting Co's EV-to-FCF too high?
Hangzhou Tigermed Consulting Co's current EV-to-FCF of 44.77 is 46% below median its 10-year median of 82.36. Over the past 10 years, this metric has ranged from a low of 30.70 to a high of 245.02. The Medical Diagnostics & Research industry median EV-to-FCF is 25.47. Hangzhou Tigermed Consulting Co's value of 44.77 is 75.8% above this industry median. Based on the distribution chart, Hangzhou Tigermed Consulting Co ranks #71 out of 99 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Hangzhou Tigermed Consulting Co has a GF Score™ of 88/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hangzhou Tigermed Consulting Co's EV-to-FCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Hangzhou Tigermed Consulting Co ranks #71 out of 99 companies for EV-to-FCF. This places Hangzhou Tigermed Consulting Co in the lower half of its industry. The industry median EV-to-FCF is 25.47. Hangzhou Tigermed Consulting Co's value of 44.77 is 75.8% above this benchmark. Historically, Hangzhou Tigermed Consulting Co's own EV-to-FCF has ranged from 30.70 to 245.02 over the past decade. While the company's 10-year median is 82.36 vs. the industry median of 25.47, Hangzhou Tigermed Consulting Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 25.47, based on 99 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hangzhou Tigermed Consulting Co's current EV-to-FCF of 44.77 is 75.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Hangzhou Tigermed Consulting Co and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 25.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hangzhou Tigermed Consulting Co's current EV-to-FCF is 44.77, which is 46% below median its own 10-year median of 82.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hangzhou Tigermed Consulting Co stock overvalued right now?
Based on GuruFocus' analysis, Hangzhou Tigermed Consulting Co (FRA:5HZ1) is currently considered Modestly Undervalued. The stock's GF Value™ is €5.01, compared to a current price of €4.16 — trading 17% below its estimated fair value. The current EV-to-FCF is 44.77, which is 46% below median its 10-year median of 82.36 and 75.8% above the Medical Diagnostics & Research industry median of 25.47. Hangzhou Tigermed Consulting Co's overall GF Score™ is 88/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Hangzhou Tigermed Consulting Co (FRA:5HZ1), the current EV-to-FCF is 44.77 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hangzhou Tigermed Consulting Co (FRA:5HZ1) Overvalued in 2026?
Based on GuruFocus' analysis, Hangzhou Tigermed Consulting Co stock appears to be undervalued.
The current stock price of €4.16 is trading 17% below its estimated GF Value™ of €5.01.
GuruFocus considers Hangzhou Tigermed Consulting Co to be Modestly Undervalued.
Key valuation signals for FRA:5HZ1:
EV-to-FCF: 44.77 (46% below median its 10-year median of 82.36)
GF Value™: €5.01 vs. price of €4.16 (17% below fair value)
Industry Position: 75.8% above the Medical Diagnostics & Research median (#71 of 99)
No single metric tells the full story. See the FRA:5HZ1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hangzhou Tigermed Consulting Co Business Description
Hangzhou Tigermed Consulting Co Ltd is a China-based provider of comprehensive biopharmaceutical R&D services, with an expanding world-wide presence. The Group is principally engaged in CRO services.
88GF Score
Get the complete analysis for FRA:5HZ1
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5HZ1 has been successfully added to your 
